https://www.selleckchem.com/pr....oducts/cerdulatinib.
More importantly, they do not completely eliminate the risk of a residual fibrotic process and the development of hepatocellular carcinoma. For all these reasons, the development of a prophylactic vaccine against hepatitis C remains a necessity. Modeling studies have shown that such a vaccine, even if only partially protective, would reduce the epidemic in the highly exposed drug-user population. If used in combination with the hepatitis B vaccine, it could contribute to WHO global viral hepatitis control plan. This article is prot
Like
Comment
Share
